Close Menu

More articles about Business, Policy & Funding

The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi, an approach that has been shown to sensitize cancer cells to chemotherapy.

The patent applications were filed by Thermo Fischer Scientific and licensed to RXi.

IP Update: Oct 1, 2009


USPTO Publishes Five Patents and Twelve Patent Applications Related to RNAi

Since the FDA has indicated that most IVDMIAs will have to undergo either 510(k) or premarket approval, the IoM's recommendations will certainly have implications for this subset of devices.

The Yale spinout's technology involves attaching "high densities of application-specific molecules to the surfaces of biodegradable, polymeric particles ranging in size from tens of nanometers to hundreds of microns."

Among the companies receiving funding were Isis Pharmaceuticals, Aparna Biosciences, Armagen Technologies, Omm Scientific, TekShifa, Optimum Therapeutics, and Effigene Pharmaceuticals.

The transaction "provides the company with additional financial resources to fund acquisitions and support bringing [its] projects and pipeline of novel drugs and products to market," according to Opko Chairman and CEO Phillip Frost.

The patent application — 2003-532675 — is owned by the Max Planck Institute, but is exclusively licensed to miRNA drug developer and Alnylam/Isis joint venture Regulus Therapeutics.

IP Update: Sep 24, 2009


USPTO Published Eight Patents, Five Patent Applications Related to RNAi

CEO Peter Meldrum said at a conference this week that Myriad's sales force "provides doctors [with] the tools to do counseling" in-house, and as a result, physicians can bill insurers directly for the service.

The suit is the second that Life Tech has filed in as many weeks. It is also the second suit filed recently claiming that Illumina's Genome Analyzer infringes DNA amplification IP.

A Roche official said that a primary focus for the company is launching drug/diagnostic combination treatments through its personalized healthcare franchise, since such products are differentiated from others on the market, may go through regulatory approval faster, and justify higher pricing.

While CombiMatrix did not disclose the terms within which a recently hired investment bank will serve as its "financial and strategic advisor," such moves typically are overtures to mergers, acquisitions, or asset divestitures.

Funding Update: Sep 22, 2009


NSF Microarray Grants Awarded July 15 — Sept. 15, 2009

Life Technologies claims that Biosearch is infringing five patents related to fluorescent probes used in real-time PCR.

Speaking after the firm's presentation Monday at the UBS Global Life Sciences Conference, Fluidigm CFO Vikram Jog told GenomeWeb Daily News that the company still intends to go public, but the timing remains uncertain.

Three German labs have accredited the MALDI Biotyper.

The USPTO said that since the co-assignees of the Tuschl-I IP “have divergent interests, no one side can reasonably expect or be permitted to control the prosecution of [the] patent application [at issue] to the exclusion of the others.”

The subsidiary will be located in San Diego, Calif., and will be led by Santaris Chief Development Office Arthur Levin, who was previously senior vice president of drug development at antisense shop Isis Pharmaceuticals.

Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.